Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in ...
BRAFTOVI in combination with cetuximab and mFOLFOX6 was granted accelerated approval by the FDA in December 2024 based on objective response rate (ORR) results, one of the BREAKWATER trial’s dual ...
The U.S. Food and Drug Administration (FDA) has approved a label change for Pfizer Inc.'s (NYSE: PFE) Depo-Provera contraceptive injection, adding a warning about the risk of meningioma, a type of ...
The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1 Shipping of the LP.8.1-adapted vaccine will ...
Pfizer's COVID Vaccine for Kids Under 5 , Moves Closer to FDA Approval . Pfizer announced on June 1 that its application to the Food and Drug Administration (FDA) for the vaccine was complete. Pfizer ...